The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“…tumor sensitivity to immune effectors, tumor foreignness, general immune status, immune cell infiltration, absence of checkpoint molecule expression, absence of soluble inhibitors such as interleukin-1 and interleukin-6, and absence of inhibitory tumor metabolism (Blank et al., 2016).”
Self-citationCharoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608
Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392
“…including ‘‘foreignness’’ (includingmutational load) (Snyder et al., 2014), aspects of tumor metabolism (such as glucose metabolism), and factors affecting tumor sensitivity to immune effectors (including human leukocyte antigen [HLA] and interferon gamma gene expression) (Blank et al., 2016).”
BackgroundTreatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302
Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,299
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135
“Treatment failure may be explained at many different levels that include a low number of immunogenic antigens, defective antigen presentation, and/or the expression of alternative immune checkpoint molecules (Blank et al., 2016; Dijkstra et al., 2016; Pitt et al., 2016; Sharma et al., 2017).”
BackgroundDong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Self-citationDe-novo and acquired resistance to immune checkpoint targeting
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 559
Tumeh, P. C., Hellmann, M. D., Hamid, O., Tsai, K. K., Loo, K. L., Gubens, M. A., Rosenblum, M., Harview, C. L., Taube, J. M., Handley, N., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0325 · Cited by 560
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Self-citationComparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Camidge, D. R., Doebele, R. C., & Kerr, K. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0173-9 · Cited by 511
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
Combining Nanomedicine and Immunotherapy
Shi, Y., & Lammers, T. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00148 · Cited by 457
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Yuen, K. C., Liu, L.-F., Gupta, V., Madireddi, S., Keerthivasan, S., Li, C., Rishipathak, D., Williams, P., Kadel, E. E., Koeppen, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0860-1 · Cited by 429
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler, J. H., Hanks, B. A., & Khasraw, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 418
Enhancing anti-tumour efficacy with immunotherapy combinations
Meric-Bernstam, F., Larkin, J., Tabernero, J., & Bonini, C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32598-8 · Cited by 409
Tumor organoid–T-cell coculture systems
Cattaneo, C. M., Dijkstra, K. K., Fanchi, L. F., Kelderman, S., Kaing, S., van Rooij, N., van den Brink, S., Schumacher, T. N., & Voest, E. E. (2020) · Nature Protocols · doi:10.1038/s41596-019-0232-9 · Cited by 410
Xia, L., Liu, Y., & Wang, Y. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s05 · Cited by 394
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel-Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 359
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Fairfax, B. P., Taylor, C. A., Watson, R. A., Nassiri, I., Danielli, S., Fang, H., Mahé, E. A., Cooper, R., Woodcock, V., Traill, Z., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0734-6 · Cited by 341
Xu, X. R., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 325
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Biomarkers of response to PD-1/PD-L1 inhibition
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.06.001 · Cited by 318
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Are innovation and new technologies in precision medicine paving a new era in patients centric care?
Seyhan, A. A., & Carini, C. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1864-9 · Cited by 299
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
Cho, J.-W., Hong, M. H., Ha, S.-J., Kim, Y.-J., Cho, B. C., Lee, I., & Kim, H. R. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00493-8 · Cited by 259
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma
Fankhauser, M., Broggi, M. A. S., Potin, L., Bordry, N., Jeanbart, L., Lund, A. W., Da Costa, E., Hauert, S., Rincon-Restrepo, M., Tremblay, C., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4712 · Cited by 259
Kundu, M., Butti, R., Panda, V. K., Malhotra, D., Das, S., Mitra, T., Kapse, P., Gosavi, S. W., & Kundu, G. C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01990-4 · Cited by 250
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Quispel-Janssen, J., van der Noort, V., de Vries, J. F., Zimmerman, M., Lalezari, F., Thunnissen, E., Monkhorst, K., Schouten, R., Schunselaar, L., Disselhorst, M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.038 · Cited by 255
Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade
Bonavita, E., Bromley, C. P., Jonsson, G., Pelly, V. S., Sahoo, S., Walwyn-Brown, K., Mensurado, S., Moeini, A., Flanagan, E., Bell, C. R., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.020 · Cited by 248
Thomas, A., Necchi, A., Muneer, A., Tobias-Machado, M., Tran, A. T. H., Van Rompuy, A.-S., Spiess, P. E., & Albersen, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00246-5 · Cited by 247
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
Lesterhuis, W. J., Bosco, A., Millward, M. J., Small, M., Nowak, A. K., & Lake, R. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.233 · Cited by 243
A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors
Pavesi, A., Tan, A. T., Koh, S., Chia, A., Colombo, M., Antonecchia, E., Miccolis, C., Ceccarello, E., Adriani, G., Raimondi, M. T., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89762 · Cited by 241
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Self-citationCombining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown, J. S., Sundar, R., & Lopez, J. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.376 · Cited by 231
Gorris, M. A. J., Halilovic, A., Rabold, K., van Duffelen, A., Wickramasinghe, I. N., Verweij, D., Wortel, I. M. N., Textor, J. C., de Vries, I. J. M., & Figdor, C. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701262 · Cited by 222
Elinav, E., Garrett, W. S., Trinchieri, G., & Wargo, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0155-3 · Cited by 215
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 210
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Wang, Y., Wang, H., Yao, H., Li, C., Fang, J.-Y., & Xu, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00536 · Cited by 209
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 206
Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J.-M., Lee, S.-H., Ahn, J. S., Cheon, J., Min, Y. J., Park, S.-H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 205
Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer
Ensenyat-Mendez, M., Llinàs-Arias, P., Orozco, J. I. J., Íñiguez-Muñoz, S., Salomon, M. P., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681476 · Cited by 201
Tinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
Hepatic metastasis from colorectal cancer
Kow, A. W. C. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.08.06 · Cited by 193
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
The GLASS Consortium, Aldape, K., Amin, S. B., Ashley, D. M., Barnholtz-Sloan, J. S., Bates, A. J., Beroukhim, R., Bock, C., Brat, D. J., Claus, E. B., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy020 · Cited by 180
Zhao, W., & Sher, X. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006457 · Cited by 168
Welters, M. J. P., Ma, W., Santegoets, S. J. A. M., Goedemans, R., Ehsan, I., Jordanova, E. S., van Ham, V. J., van Unen, V., Koning, F., van Egmond, S. I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2140 · Cited by 167
Next-generation computational tools for interrogating cancer immunity
Finotello, F., Rieder, D., Hackl, H., & Trajanoski, Z. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0166-7 · Cited by 162
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 164
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.005 · Cited by 167
Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies.
Cheng, J., Zhao, L., Zhang, Y., Qin, Y., Guan, Y., Zhang, T., Liu, C., & Zhou, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01237 · Cited by 153
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00803-9 · Cited by 153
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Tarantino, P., Corti, C., Schmid, P., Cortés, J., Mittendorf, E. A., Rugo, H. S., Tolaney, S. M., Bianchini, G., André, F., & Curigliano, G. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00386-1 · Cited by 164
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 164
Ramachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G. J., Bath, N. M., Tipping, A. J., Melchiori, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0762-2 · Cited by 158
Schirris, Y., Gavves, E., Nederlof, I., Horlings, H. M., & Teuwen, J. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102464 · Cited by 196
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 148
Kordbacheh, T., Honeychurch, J., Blackhall, F. H., Finn, C. F., & Illidge, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx790 · Cited by 151
Broggi, M. A. S., Maillat, L., Clement, C. C., Bordry, N., Corthésy, P., Auger, A., Matter, M., Hamelin, R., Potin, L., Demurtas, D., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181618 · Cited by 143
Precision immunoprofiling by image analysis and artificial intelligence
Koelzer, V. H., Sirinukunwattana, K., Rittscher, J., & Mertz, K. D. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2485-z · Cited by 151
Competitive glucose metabolism as a target to boost bladder cancer immunotherapy
Afonso, J., Santos, L. L., Longatto‐Filho, A., & Baltazar, F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0263-6 · Cited by 144
Mechanisms of M. tuberculosis Immune Evasion as Challenges to TB Vaccine Design
Ernst, J. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.06.004 · Cited by 140
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 146
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw, M., Reardon, D. A., Weller, M., & Sampson, J. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1135 · Cited by 143
Nosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P. C., Grimes, B. A., Loo, K. L., Algazi, A. P., Nguyen‐Kim, T. D. L., Levesque, M. P., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 133
Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase
Guan, X., Chen, J., Hu, Y., Lın, L., Sun, P., Tian, H., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.039 · Cited by 130
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
Hommes, J. W., Verheijden, R. J., Suijkerbuijk, K. P. M., & Hamann, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585311 · Cited by 139
Spatially mapping the immune landscape of melanoma using imaging mass cytometry
Moldoveanu, D., Ramsay, L., Lajoie, M., Anderson-Trocmé, L., Lingrand, M., Berry, D., Perus, L. J. M., Wei, Y., Moraes, C., Alkallas, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi5072 · Cited by 141
Precision Medicine Is Not Just Genomics: The Right Dose for Every Patient
Peck, R. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052446 · Cited by 140
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
van Dijk, N., Funt, S. A., Blank, C. U., Powles, T. B., Rosenberg, J. E., & van der Heijden, M. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.022 · Cited by 125
Maron, S. B., Alpert, L., Kwak, H. A., Lomnicki, S., Chase, L. M., Xu, D., O’Day, E., Nagy, R. J., Lanman, R. B., Cecchi, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1260 · Cited by 130
Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management
Colli, L. M., Machiela, M. J., Zhang, H., Myers, T. A., Jessop, L., Delattre, O., Yu, K. F., & Chanock, S. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3338 · Cited by 128
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 132
The clinical utility of tumor mutational burden in non-small cell lung cancer
Greillier, L., Tomasini, P., & Barlési, F. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.08 · Cited by 131
Computational Prediction and Validation of Tumor-Associated Neoantigens
Roudko, V., Greenbaum, B. D., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 134
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas, D. C., Theocharopoulos, C., Koutouratsas, T., Haanen, J. B. A. G., & Gogas, H. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102499 · Cited by 128
Buchan, S. L., Fallatah, M., Thirdborough, S. M., Taraban, V. Y., Rogel, A., Thomas, L. J., Penfold, C. A., He, L.-Z., Curran, M. A., Keler, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3057 · Cited by 114
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.